LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

ImmunityBio Inc

Fermé

SecteurSoins de santé

2.82 6.42

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.66

Max

2.9

Chiffres clés

By Trading Economics

Revenu

-70M

-130M

Ventes

9M

17M

BPA

-0.15

Marge bénéficiaire

-785.046

Employés

680

EBITDA

-24M

-64M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+144.18% upside

Dividendes

By Dow Jones

Prochains Résultats

8 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-324M

2.1B

Ouverture précédente

-3.6

Clôture précédente

2.82

Sentiment de l'Actualité

By Acuity

50%

50%

173 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

ImmunityBio Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 mai 2025, 17:20 UTC

Principaux Mouvements du Marché

ImmunityBio Slides Following FDA Refusal-to-File Letter

5 mai 2025, 11:38 UTC

Principaux Mouvements du Marché

ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application

29 janv. 2025, 15:59 UTC

Principaux Mouvements du Marché

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

24 oct. 2024, 13:50 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Comparaison

Variation de prix

ImmunityBio Inc prévision

Objectif de Prix

By TipRanks

144.18% hausse

Prévisions sur 12 Mois

Moyen 6.08 USD  144.18%

Haut 8 USD

Bas 4.25 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2 / 2.63Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

173 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.